What a Clinical Overview Must Contain for an EU Hybrid Application
Written byNeta Kela, PhDFounder & Managing Partner
Short answer: In a hybrid application under Article 10(3) of Directive 2001/83/EC, the Clinical Overview carries the scientific argument. It must explain exactly how your product differs from the reference medicinal product, show that the bridging data you generated covers each difference, and conclude that the benefit-risk balance established for the reference product still applies. An overview that only summarises studies, without that argument, is the most common reason for avoidable questions at Day 120.
What is a hybrid application?
A hybrid application relies partly on the results of the reference product's preclinical tests and clinical trials, and partly on new data. Article 10(3) applies when a product does not meet the strict definition of a generic, or when bioequivalence cannot be shown through bioavailability studies alone. Typical triggers are a change in strength, pharmaceutical form, route of administration or therapeutic indication versus the reference product.
The applicant does not repeat the reference product's full development. Instead, it provides the results of appropriate preclinical or clinical studies that address the differences. The Clinical Overview is where those results are interpreted.
What must the Clinical Overview cover?
The structure follows ICH M4E for CTD Module 2.5. For a hybrid application, the sections that do the heavy lifting are:
- Product development rationale. State the reference medicinal product, the legal basis, and each difference from the reference product in a single clear table. Assessors should not have to reconstruct this from Module 1.
- Overview of biopharmaceutics. If you rely on a pharmacokinetic bridge, explain why the PK comparison is sufficient for each difference, and where it is not, what additional data closes the gap.
- Overview of clinical pharmacology. Address exposure differences explicitly. A higher Cmax or a different Tmax needs a clinical interpretation, not just a number.
- Overview of efficacy and safety. Where you rely on the reference product's data, say so precisely and justify why it transfers. Where you generated new data, assess it critically, including its limitations.
- Benefit and risk conclusions. Tie every difference back to the benefit-risk balance. This is the section assessors read first.
Where do assessors push back?
From EU assessment reports for hybrid products, the recurring issues are predictable:
- Unjustified differences. A new strength or formulation is described but its clinical relevance is not argued.
- Bridging that does not match the claim. A PK study supports one population or dose, while the proposed label covers more.
- Literature used as decoration. Published studies are listed without an assessment of their quality or relevance to your product.
- Product information drift. The proposed SmPC deviates from the reference product without the overview explaining why.
Why the signing expert matters
Article 12 of Directive 2001/83/EC requires that the overviews are drawn up and signed by experts with the necessary technical or professional qualifications, and that their CV is included. The expert is personally accountable for the critical assessment. For a hybrid file, that means the expert must be able to defend the scientific argument for each difference, not only the writing.
What about the EU pharma package?
The new EU pharmaceutical legislation was politically agreed in December 2025 and applies roughly 24 months after entry into force. Applications submitted before the date of application continue under the current rules. For files in preparation today, Directive 2001/83/EC remains the legal basis.
Sources
- EMA: Generic and hybrid applications: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/generic-hybrid-medicines/generic-hybrid-applications
- EMA: Procedural advice for users of the centralised procedure for generic/hybrid applications: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-users-centralised-procedure-generic-hybrid-applications_en.pdf
- EUPATI: Hybrid application: https://learning.eupati.eu/mod/book/view.php?id=908&chapterid=875
- HSF Kramer: The EU Pharma Package is finally here: https://www.hsfkramer.com/notes/ip/2026-04/the-eu-pharma-package-finally-here-what-it-changes-and-what-it-means
Frequently Asked Questions
How PXM Helps With This
Related
Part of FDA & CMC Readiness. Start from the pillar: Operate practice, FDA Regulatory Readiness, CMC & Manufacturing, FDA Expedited Pathways, EU Regulatory Pathways
Well-Established Use Applications: Building a Bibliographic Clinical Overview That Holds Up
How to build the Clinical Overview for an EU well-established use application under Article 10a: the ten-year test, literature selection, and how to bridge your product to the published evidence.
How to Choose an Independent Clinical Expert for Your EU Dossier
What Article 12 of Directive 2001/83/EC requires from the Clinical and Nonclinical Expert, what to look for when you appoint one, and the questions to ask before they sign.
FDA National Priority Voucher (CNPV): Should You Apply?
What the FDA national priority voucher (CNPV) offers in 2026, how it compares to other expedited programs, and what EU sponsors need ready first.
Get notified when we publish new funding and regulatory guides
Practical guidance on FDA and EMA strategy, CMC readiness, and non-dilutive funding — sent only when there is something worth reading.